TheStreet
JIM CRAMERINVESTINGPERSONAL FINANCERETIREMENTTECHNOLOGYMARKETSHOW-TOVIDEOFINANCIAL ADVISOR CENTER
Search

LATEST NEWS

Jim Cramer on Brexit: UK Stocks Are Too Expensive
Play
JIM CRAMER

Too Much Risk?: Cramer's 'Mad Money' Recap (Friday 1/10/20)

PRESS RELEASES

REGENXBIO Announces Presentations At The Angiogenesis, Exudation, And Degeneration 2021 Conference

PRESS RELEASES

REGENXBIO Announces Presentations At The 17th Annual WORLDSymposium™ 2021

PRESS RELEASES

REGENXBIO Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares

PRESS RELEASES

REGENXBIO To Present At The 39th Annual J.P. Morgan Healthcare Conference

PRESS RELEASES

REGENXBIO Announces Pricing Of Public Offering Of Common Stock

PRESS RELEASES

REGENXBIO Announces Proposed Public Offering Of Common Stock

PRESS RELEASES

REGENXBIO Announces Update On RGX-314 And Pivotal Program For The Treatment Of Wet AMD And New Gene Therapy Program For The Treatment Of Duchenne Muscular Dystrophy

PRESS RELEASES

REGENXBIO Announces Agreement To Monetize Portion Of Zolgensma® Royalties For $200 Million

PRESS RELEASES

REGENXBIO Announces Dosing Of First Patient In Phase II ALTITUDE™ Trial Of RGX-314 For The Treatment Of Diabetic Retinopathy Using Suprachoroidal Delivery

PRESS RELEASES

REGENXBIO Announces Dosing Of First Patient In Phase I/II Trial Of RGX-111 For The Treatment Of Mucopolysaccharidosis Type I

PRESS RELEASES

REGENXBIO To Present At Upcoming Investor Conferences

PRESS RELEASES

REGENXBIO Announces Presentations At The American Academy Of Ophthalmology 2020 Annual Meeting

PRESS RELEASES

REGENXBIO To Present At Upcoming Investor Conferences

PRESS RELEASES

REGENXBIO To Host Conference Call On November 4 To Discuss Third Quarter 2020 Financial Results And Recent Operational Highlights

PRESS RELEASES

REGENXBIO To Receive $80.0 Million Milestone Payment From Novartis AG

PRESS RELEASES

REGENXBIO Announces Continued Progress And Expansion Of Clinical Development Program For RGX-121 For The Treatment Of Mucopolysaccharidosis Type II (MPS II)

PRESS RELEASES

REGENXBIO To Participate In Upcoming Investor Conferences

PRESS RELEASES

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating REGENXBIO Inc. For Potential Breaches Of Fiduciary Duty By Its Board Of Directors

PRESS RELEASES

REGENXBIO To Participate In Upcoming Investor Conferences

PRESS RELEASES

REGENXBIO To Host Conference Call On August 6 To Discuss Second Quarter 2020 Financial Results And Recent Operational Highlights

PRESS RELEASES

REGENXBIO Provides Update On Progress Of Clinical Programs For Rare Genetic Neurodegenerative Diseases

PRESS RELEASES

REGENXBIO To Present At The Raymond James Human Health Innovation Conference

PRESS RELEASES

REGENXBIO To Host Conference Call On May 7 To Discuss First Quarter 2020 Financial Results And Recent Operational Highlights

PRESS RELEASES

REGENXBIO Announces Presentations At The American Society Of Gene And Cell Therapy's 23rd Annual Meeting